Meeting
2023 ASCO Genitourinary Cancers Symposium
Ga-68 PSMA-11 impacting prostate cancer management in a real-world setting: A pilot experience using the total-body PET/CT scanner.
Authors
Harshad R Kulkarni
BAMF Health, Grand Rapids, MI
Harshad R Kulkarni , Dan Rogers , Kevin Maupin , Todd Faasse , Jens Forsberg , Matt DeLong , Brandon Robert Mancini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 62)
DOI
10.1200/JCO.2023.41.6_suppl.62
Abstract #
62
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
First Author: Ahmed M. Mahmoud
Poster
2023 ASCO Genitourinary Cancers Symposium
Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.
First Author: Bridget F. Koontz
Poster
2021 ASCO Annual Meeting
Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study).
First Author: Juliano J Cerci
Poster
2017 ASCO Annual Meeting
Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer.
First Author: Tom Hope